The Union Cycliste Internationale (UCI) confirms that British rider Christopher Froome was notified of an Adverse Analytical Finding (AAF) of Salbutamol in excess of 1000ng/ml (*) in a sample collected during the Vuelta a España on 7 September 2017. The rider was notified of the AAF on 20 September 2017. The anti-doping control was planned and carried out by the Cycling Anti-Doping Foundation (CADF), the independent body mandated by the UCI, in charge of defining and implementing the anti-doping strategy in cycling. The analysis of the B sample has confirmed the results of the rider’s A sample and the proceedings are being conducted in line with the UCI Anti-Doping Rules. As a matter of principle, and whilst not required by the World Anti-Doping Code, the UCI systematically reports potential anti-doping rule violations via its website when a mandatory provisional suspension applies. Pursuant to Article 7.9.1. of the UCI Anti-Doping Rules, the presence of a Specified Substance such as Salbutamol in a sample does not result in the imposition of such mandatory provisional suspension against the rider. At this stage of the procedure, the UCI will not comment any further on this matter. (*) WADA’s Prohibited List provides that: “The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of the therapeutic dose (by inhalation) up to the maximum dose indicated above.”